ASX Dividend Stocks To Enhance Your Portfolio Income
Name
Dividend Yield
Dividend Rating
Super Retail Group (ASX:SUL)
7.74%
★★★★★☆
Sugar Terminals (NSX:SUG)
8.20%
★★★★★☆
Ricegrowers (ASX:SGLLV)
6.36%
★★★★★☆
Nick Scali (ASX:NCK)
3.25%
★★★★★☆
MFF Capital Investments (ASX:MFF)
3.62%
★★★★★☆
Lycopodium (ASX:LYL)
6.59%
★★★★★☆
Lindsay Australia (ASX:LAU)
7.13%
★★★★★☆
IPH (ASX:IPH)
6.89%
★★★★★☆
Fiducian Group (ASX:FID)
4.25%
★★★★★☆
Accent Group (ASX:AX1)
6.62%
★★★★★☆
Click here to see the full list of 28 stocks from our Top ASX Dividend Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Kina Securities Limited operates in Papua New Guinea, offering commercial banking, financial services, fund administration, investment management, and share brokerage services with a market cap of A$378.32 million.
Operations: Kina Securities Limited generates revenue through its Wealth Management segment, contributing PGK 47.36 million, and its Banking & Finance (Including Corporate) segment, which accounts for PGK 421.46 million.
Dividend Yield: 7.4%
Kina Securities offers a compelling dividend yield of 7.36%, placing it in the top quartile among Australian dividend payers. Its dividends are covered by earnings, with a payout ratio of 74.8%, expected to improve to 68.6% in three years. However, its dividend history is unstable and has been volatile over the past nine years. Additionally, Kina faces challenges with a high level of bad loans (11.1%), impacting its financial stability.
Delve into the full analysis dividend report here for a deeper understanding of Kina Securities.
Upon reviewing our latest valuation report, Kina Securities' share price might be too pessimistic.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Ridley Corporation Limited, with a market cap of A$1.06 billion, provides animal nutrition solutions in Australia through its subsidiaries.
Operations: Ridley Corporation Limited generates revenue from its animal nutrition solutions through two main segments: Bulk Stockfeeds, contributing A$894.26 million, and Packaged/Ingredients, adding A$389.70 million.
Dividend Yield: 3.4%
Ridley's dividend payments are covered by earnings and cash flows, with payout ratios of 75% and 41.6%, respectively, though its dividend history has been volatile over the past decade. Recent events include a planned CFO transition linked to the acquisition of Incitec Pivot Fertilisers' distribution business and a follow-on equity offering raising A$125.68 million, which may impact shareholder value due to dilution concerns from new share issuance.
Click here to discover the nuances of Ridley with our detailed analytical dividend report.
Our valuation report here indicates Ridley may be undervalued.
Simply Wall St Dividend Rating: ★★★★★☆
Overview: Super Retail Group Limited operates as a retailer of automotive, sports, and outdoor leisure products across Australia and New Zealand, with a market capitalization of A$3.47 billion.
Operations: Super Retail Group's revenue is derived from its segments: Super Cheap Auto with A$1.51 billion, Rebel at A$1.32 billion, Boating, Camping and Fishing (BCF) excluding Macpac at A$912.60 million, and Macpac contributing A$215.80 million.
Dividend Yield: 7.7%
Super Retail Group's dividends are supported by earnings and cash flows, with payout ratios of 68.8% and 68%, respectively, although the dividend history has been volatile over the past decade. The company offers a competitive dividend yield in the top 25% of Australian payers. Trading at a lower price-to-earnings ratio than the market average suggests good value. Recent sales data shows growth of over 4% for key periods in 2025, indicating positive business momentum.
Take a closer look at Super Retail Group's potential here in our dividend report.
The analysis detailed in our Super Retail Group valuation report hints at an deflated share price compared to its estimated value.
Investigate our full lineup of 28 Top ASX Dividend Stocks right here.
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:KSL ASX:RIC and ASX:SUL.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
39 minutes ago
- Bloomberg
Stock Movers: Coinbase, Kenvue, Synopsis
On this episode of Stock Movers: - Coinbase (COIN) share are gaining after Argus Research Corp initiated coverage of the stock with a recommendation of buy and a $400 price target. The stock has 20 analyst buy, 16 hold and four sell ratings with an average price target of $315, according to data compiled by Bloomberg; shares are up 56% year-to-date. - Kenvue (KVUE) is moving after it said Chief Executive Officer Thibaut Mongon will leave the company as it continues to revamp the maker of Tylenol, Neutrogena and Listerine brands. Board director Kirk Perry will take over as interim CEO, effective immediately, and the company has commenced a search for a new CEO. The company's board chair Larry Merlo said "The board's strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the Company's portfolio and how it operates" - Tesla (TSLA) shares are moving amid continued tension between Elon Musk and President Trump. Other news items traders are watching include Chinese rival BYD planning to ramp up its expansion efforts in Saudi Arabia, building on momentum from Tesla Inc.'s launch in the country. Tesla will also stand trial over claims that the company is partly to blame for a fatal 2019 crash in Florida that occurred when the Autopilot system in a Model S allegedly failed to detect a parked SUV. - Synopsis (SNPS) is moving this morning and at one point was the biggest upside mover in early trading. The company secured China's approval to buy out Ansys Inc. for $35 billion, according to Bloomberg. The buyout was already approved by European and US authorities, and Synopsys has now cleared one of the last major hurdles to a deal intended to shore up its market position.
Yahoo
40 minutes ago
- Yahoo
Is Core Natural Resources (CNR) Poised for a Future Upside?
Black Bear Value Partners, an investment management firm, published its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Black Bear Value Fund returned -3.0% in June and -10.5% in the quarter, and -11.7% YTD. The S&P 500 returned +5.1% June, +10.9% in the quarter, and +6.2% year-to-date. HFRI Value Index returned +3.1% in June, +7.7% in the quarter, and +7.1% year-to-date. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second quarter 2025 investor letter, Black Bear Value Partners highlighted stocks such as Core Natural Resources, Inc. (NYSE:CNR). Core Natural Resources, Inc. (NYSE:CNR) was formed by merging Arch Resources and CONSOL Energy in January 2025. Core Natural Resources, Inc. (NYSE:CNR) is a US-based company involved in the production, distribution, and export of metallurgical and thermal coals. The one-month return of Core Natural Resources, Inc. (NYSE:CNR) was 3.95%, and its shares lost 28.27% of their value over the last 52 weeks. On July 11, 2025, Core Natural Resources, Inc. (NYSE:CNR) stock closed at $75.60 per share with a market capitalization of $3.981 billion. Black Bear Value Partners stated the following regarding Core Natural Resources, Inc. (NYSE:CNR) in its second quarter 2025 investor letter: "Core Natural Resources, Inc. (NYSE:CNR) is the result of the merger between Consol and Arch Resources. As a combined entity they are one of the leading producers of metallurgical coal (steel) and thermal coal (energy). The Company is heavily dependent on exports so retaliatory tariffs would be damaging. At the same time, there has been a reduction in global capacity so many countries may not have much choice, especially if they need higher quality coal. A tugboat crew navigating a harbor, inching closer to a massive cargo ship. Core Natural Resources, Inc. (NYSE:CNR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 44 hedge fund portfolios held Core Natural Resources, Inc. (NYSE:CNR) at the end of the first quarter, which was 39 in the previous quarter. While we acknowledge the potential of CNR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Core Natural Resources, Inc. (NYSE:CNR) and shared billionaire David Einhorn's stock picks with huge upside potential. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala
Investment Will Accelerate PCI's Leading Position in CDMO, Delivering Life-Changing Therapies to Patients Transaction Includes Continued Investment from Partners Group PHILADELPHIA, July 14, 2025--(BUSINESS WIRE)--PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization (CDMO) focused on innovative biotherapies, today announced that it received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and supported with significant reinvestment by Mubadala Investment Company ("Mubadala"). Partners Group will also continue to support the Company with a minority investment. Financial terms of the private transaction were not disclosed. Headquartered in Philadelphia, Pennsylvania, PCI provides clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products' speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 450 successful product launches over the last five years and over 50 years in pharmaceutical services helping bring to life innovation to improve patient access and outcomes. Kohlberg and Mubadala, both of which initially invested in PCI in 2020, and Bain Capital are partnering with PCI's management team, led by Chief Executive Officer Salim Haffar, to accelerate the Company's growth trajectory, build upon its strong customer service experience, and further enable PCI clients to bring life-changing biopharmaceutical therapies to market. PCI will primarily focus on organic and inorganic growth initiatives, including expanding its suite of services and geographic reach. Leveraging global growth trends in biologics and specialized drug therapies, PCI's future investments will include expansion of existing sterile fill-finish of injectables and high potent and specialized manufacturing capacity. The strategic investment will also enable the Company's significant continued investment in the US, bolstering the nation's critical pharmaceutical manufacturing and supply chain infrastructure. Haffar said: "PCI has embarked on a purposeful journey to transform itself into a global CDMO by executing its successful growth strategy, providing industry-leading customer experience, and offering innovative and integrated supply chain solutions. I am grateful for the ongoing support of our existing investors and enthusiastically welcome Bain Capital and their deep, global healthcare and life science capabilities and expertise. Together we will grow PCI's commercial, clinical trial services, and development and manufacturing businesses to meet the future demands of our biopharmaceutical customers." Matt Jennings, Chairman of PCI and an Operating Partner of Kohlberg, commented: "PCI's world-class management team, combined with the support of experienced industry investors, has proven to be a very successful formula. We are delighted for Bain Capital to join PCI's investor base, yielding an optimal combination aligned to support Salim and the management team to execute on their growth ambitions and value creation pathways." Devin O'Reilly, Partner at Bain Capital, said: "Anchored by an innovative, advanced platform that is consistently growing and setting new standards for the industry, PCI Pharma has built a well-deserved reputation as a differentiated partner to leading biopharma companies, ensuring critical therapies reach patients safely and efficiently. We look forward to working alongside Kohlberg to build on this strong foundation." Andrew Kaplan and Christina Dix, Partners at Bain Capital added: "We are excited to leverage our industry expertise and the collaboration of our global healthcare team to support Salim and PCI's team of experienced industry leaders in the mission to drive innovation in advanced pharmaceutical services that improve patients' lives and outcomes." Chris Anderson, Senior Partner of Kohlberg, added: "We are honored to have supported PCI's transformation over the last five years into a leading global CDMO, positioned in the fastest growing markets and known for its proven experience meeting critical customer needs throughout the drug development and commercialization lifecycle. We are thrilled to be partnering with Bain Capital and are aligned to make new investments that will further elevate the Company's capabilities and growth for many years to come." Mina Hamoodi, Head of Healthcare at Mubadala, said: "Our reinvestment in PCI reflects our deep conviction in the company's mission, leadership, and long-term potential. At this important juncture, we are delighted to welcome Bain Capital, an industry-leading healthcare investor with deep expertise in growing pharma services businesses, as a partner. We look forward to partnering with Bain and Kohlberg, and working closely with PCI's outstanding management team, as the company enters its next chapter of accelerated growth." Sujit John, Managing Director, Private Equity Health & Life Vertical, Partners Group, commented: "PCI's market position, reputation, and world-class capabilities strategically position the Company to be the partner of choice for customers. We look forward to supporting PCI and the new ownership group in driving the Company into its next phase of growth." Jefferies LLC acted as lead financial advisor to PCI and Moelis & Company LLC acted as co-advisor to PCI. Morgan Stanley & Co. LLC, and BofA Securities, Inc. acted as financial advisors to Bain Capital. Citi acted as a financial advisor to Mubadala. Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as counsel to PCI and Kohlberg. Kirkland & Ellis LLP acted as counsel to Bain Capital. Skadden, Arps, Slate, Meagher & Flom LLP acted as counsel to Mubadala. Ropes & Gray LLP acted as counsel to Partners Group. About PCI Pharma Services PCI is a world-leading CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products' speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 38 sites across seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain and Australia), and over 7,500 employees working to bring life-changing therapies to patients. Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and commercialization. Its clients utilize PCI as an extension of their business, and a collaborative partner with the shared goal of improving patients' lives. For more information, visit About Kohlberg Founded in 1987, Kohlberg is a leading U.S. middle market private equity firm based in Mount Kisco, New York. The firm invests in high-quality healthcare and services companies characterized by strong market positions, recurring revenue streams and resilient end markets, which it identifies through rigorous thematic research grounded in its White Paper Program. Leveraging its team of investment and operating professionals, Kohlberg works with management teams to accelerate growth, enhance operational excellence and create value. For more information, please visit About Bain Capital Founded in 1984, Bain Capital is one of the world's leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit Follow @BainCapital on LinkedIn and X (Twitter). About Mubadala Investment Company Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi. Mubadala's $330 billion (AED 1.2 trillion) portfolio spans six continents with interests in multiple sectors and asset classes. Mubadala leverages its deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates. Headquartered in Abu Dhabi, Mubadala has additional offices in New York, London, Rio de Janeiro, San Francisco and Beijing. For more information about Mubadala Investment Company, please visit: About Partners Group Partners Group is one of the largest firms in the global private markets industry, with around 1,800 professionals and over $150 billion in overall assets under management. The firm has investment programs and custom mandates spanning private equity, private credit, infrastructure, real estate, and royalties. With its heritage in Switzerland and its primary presence in the Americas in Colorado, Partners Group is built differently from the rest of the industry. The firm leverages its differentiated culture and its operationally oriented approach to identify attractive investment themes and to transform businesses and assets into market leaders. For more information, please visit View source version on Contacts For PCI Christopher DaleTurchette Agency973-227-8080 ext. 116cdale@ For Kohlberg Amanda Shpiner/Iain HughesGasthalter & Co.212-257-4170media@ For Bain Capital Charlyn Lusk/Scott LessneStanton646-502-3549/646-502-3569clusk@ For Mubadala Salam Kitmitto+971 50 276 9286sakitmitto@ For Partners Group Prosek Partnerspro-partnersgroup@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
